Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study

Carolyn Bolton Moore, Kristin Baltrusaitis, Brookie M Best, John H Moye, Ellen Townley, Avy Violari, Barbara Heckman, Sarah Buisson, Rodica M Van Solingen-Ristea, Edmund V Capparelli, Mark A Marzinke, Elizabeth D Lowenthal, Shawn Ward, Chelsea Krotje, Ryan Milligan, Allison L Agwu, Jenny Huang, S Y Amy Cheung, Cynthia McCoig, Dwight E Yin, Gilly Roberts, Herta Crauwels, Veerle Van Eygen, Sara Zabih, Gaerolwe Masheto, Pradthana Ounchanum, Linda Aurpibul, Violet Korutaro, Aditya H Gaur, Kyle Whitson, Michael Whitton, Conn M. Harrington, Faeezah Patel, Mary E. Paul, Sherika Hanley, Kati Vandermeulen, Yu-Wei Lin, Isabelle Deprez, Kelong Han, Susan L. Ford, Jon W. Collins

Open source

DOI: 10.1016/s2352-3018(24)00344-8
Published: 2025-03
Container: The Lancet HIV
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s2352-3018-24-00344-8,
  title = {Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study},
  author = {Carolyn Bolton Moore and Kristin Baltrusaitis and Brookie M Best and John H Moye and Ellen Townley and Avy Violari and Barbara Heckman and Sarah Buisson and Rodica M Van Solingen-Ristea and Edmund V Capparelli and Mark A Marzinke and Elizabeth D Lowenthal and Shawn Ward and Chelsea Krotje and Ryan Milligan and Allison L Agwu and Jenny Huang and S Y Amy Cheung and Cynthia McCoig and Dwight E Yin and Gilly Roberts and Herta Crauwels and Veerle Van Eygen and Sara Zabih and Gaerolwe Masheto and Pradthana Ounchanum and Linda Aurpibul and Violet Korutaro and Aditya H Gaur and Kyle Whitson and Michael Whitton and Conn M. Harrington and Faeezah Patel and Mary E. Paul and Sherika Hanley and Kati Vandermeulen and Yu-Wei Lin and Isabelle Deprez and Kelong Han and Susan L. Ford and Jon W. Collins},
  year = {2025},
  journal = {The Lancet HIV},
  doi = {10.1016/s2352-3018(24)00344-8},
  url = {https://doi.org/10.1016/s2352-3018(24)00344-8}
}

RIS

TY  - JOUR
TI  - Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study
AU  - Carolyn Bolton Moore
AU  - Kristin Baltrusaitis
AU  - Brookie M Best
AU  - John H Moye
AU  - Ellen Townley
AU  - Avy Violari
AU  - Barbara Heckman
AU  - Sarah Buisson
AU  - Rodica M Van Solingen-Ristea
AU  - Edmund V Capparelli
AU  - Mark A Marzinke
AU  - Elizabeth D Lowenthal
AU  - Shawn Ward
AU  - Chelsea Krotje
AU  - Ryan Milligan
AU  - Allison L Agwu
AU  - Jenny Huang
AU  - S Y Amy Cheung
AU  - Cynthia McCoig
AU  - Dwight E Yin
AU  - Gilly Roberts
AU  - Herta Crauwels
AU  - Veerle Van Eygen
AU  - Sara Zabih
AU  - Gaerolwe Masheto
AU  - Pradthana Ounchanum
AU  - Linda Aurpibul
AU  - Violet Korutaro
AU  - Aditya H Gaur
AU  - Kyle Whitson
AU  - Michael Whitton
AU  - Conn M. Harrington
AU  - Faeezah Patel
AU  - Mary E. Paul
AU  - Sherika Hanley
AU  - Kati Vandermeulen
AU  - Yu-Wei Lin
AU  - Isabelle Deprez
AU  - Kelong Han
AU  - Susan L. Ford
AU  - Jon W. Collins
PY  - 2025
JO  - The Lancet HIV
DO  - 10.1016/s2352-3018(24)00344-8
UR  - https://doi.org/10.1016/s2352-3018(24)00344-8
ER  -

APA

Moore, C. B., Baltrusaitis, K., Best, B. M., Moye, J. H., Townley, E., Violari, A., Heckman, B., Buisson, S., Solingen-Ristea, R. M. V., Capparelli, E. V., Marzinke, M. A., Lowenthal, E. D., Ward, S., Krotje, C., Milligan, R., Agwu, A. L., Huang, J., Cheung, S. Y. A., McCoig, C., Yin, D. E., Roberts, G., Crauwels, H., Eygen, V. V., Zabih, S., Masheto, G., Ounchanum, P., Aurpibul, L., Korutaro, V., Gaur, A. H., Whitson, K., Whitton, M., Harrington, C. M., Patel, F., Paul, M. E., Hanley, S., Vandermeulen, K., Lin, Y., Deprez, I., Han, K., Ford, S. L., & Collins, J. W. (2025). Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study. The Lancet HIV. https://doi.org/10.1016/s2352-3018(24)00344-8

Source records

crossref · retrieved 2026-09-26T10:39:47.159Z